UK Markets open in 3 hrs 1 mins

Pandora Media, Inc. (P)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
8.32+0.13 (+1.59%)
At close: 4:01PM EDT

8.24 -0.08 (-0.96%)
After hours: 4:52PM EDT

People also watch
YELPGRPNLNKDZNGAZ
Full screen
Previous close8.19
Open8.22
Bid0.00 x 0
Ask0.00 x 0
Day's range8.17 - 8.35
52-week range6.76 - 14.95
Volume3,405,044
Avg. volume9,251,778
Market cap2.02B
Beta-0.84
PE ratio (TTM)-3.43
EPS (TTM)N/A
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
Trade prices are not sourced from all markets
All
News
Press releases
  • Pandora Launches Video Plus for All Advertisers
    Business Wire15 hours ago

    Pandora Launches Video Plus for All Advertisers

    Pandora today announced that Video Plus is now available to all advertisers. The new ad product enables brands to pay only when users watch 15 seconds of a video ad. In exchange for watching the ad, listeners unlock features that are typically only available with a subscription to Pandora Plus or Pandora Premium: the ability to skip more songs and replay tracks.

  • Business Wire7 days ago

    Ingersoll Rand to Present at the Morgan Stanley 5th Annual Laguna Conference

    SWORDS, Ireland--(BUSINESSWIRE)-- Michael W. Lamach, chairman and chief executive officer, and Susan K. Carter, senior vice president and chief financial officer, of Ingersoll Rand plc (NYSE:IR), a world ...

  • Business Wire9 days ago

    Zymeworks Presents Additional Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the European Society for Medical Oncology 2017 Congress (“ESMO”)

    TSX: ZYME) a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, today provided additional data from the dose escalation portion of its Phase 1 study of ZW25, a novel Azymetric™ bispecific antibody targeting two distinct domains of the HER2 receptor. The HER2–mediated signaling pathway is believed to contribute to tumor growth in a number of different cancers. The expanded dataset includes an additional three-month follow-up for on-study patients following the American Society of Clinical Oncology (“ASCO”) conference in June 2017, as well as safety data on six new patients.

By using Yahoo, you agree that we and our partners may use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more; Yahoo is now part of ‘Oath’ and a member of the Verizon family of companies. As of 15 September 2017, we plan to share some user information within our new family. Learn more